Bulletin n°90
Traitements
-
Combinaison de traitements localisés et systémiques (2)
-
Menée in vitro et in vivo, cette étude évalue la réponse de cellules et de tumeurs de cancer de la prostate à un traitement combinant un inhibiteur de PARP et une radiothérapie
Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation
2011
-
Mené sur 93 patients atteints d'un cancer du poumon non à petites cellules de stade IIIA/B, cet essai de phase II évalue le cétuximab en combinaison avec une chimioradiothérapie
Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324
Journal of Clinical Oncology, 2011
-
-
Traitements systémiques : applications cliniques (5)
-
Cette étude évalue l'association entre l'indice de masse corporelle et l'efficacité d'un traitement endocrinien adjuvant chez des patientes autrichiennes atteintes d'un cancer du sein avant la ménopause
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Journal of Clinical Oncology, 2011
-
Cet article passe en revue les travaux récents sur les effets à long terme des traitements adjuvants du cancer du sein
Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects
Journal of Clinical Oncology, 2011
-
Mené sur 342 patients atteints d'un cancer métastatique du pancréas dans 48 centres hospitaliers français, cet essai de phase II-III compare le traitement combiné FOLFIRINOX avec la gemcitabine
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
New England Journal of Medicine, 2011
-
Mené sur 459 patients âgés, fragiles et atteints d'un cancer colorectal métastatique dans 61 centres hospitaliers britanniques, cet essai factoriel randomisé évalue quatre protocoles de chimiothérapie
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
The Lancet, 2011
-
A partir de de quatre essais ayant inclus près de 2 000 patients atteints d'un cancer du poumon non à petites cellules de stade avancé, cette méta-analyse compare le gefitinib avec une chimiothérapie pour un traitement de première ligne
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
Lung Cancer, 2011
-
-
Traitements systémiques : découverte et développement (8)
-
Mené sur 31 patientes atteintes d'un cancer du sein HER2+ métastatique, cet essai de phase II évalue l'ajout de tanespimycine, un inhibiteur de la protéine de choc thermique HSP90, au trastuzumab
HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab
Clinical Cancer Research, 2011
-
Mené sur 176 patients atteints d'un cancer de la prostate, cet essai randomisé évalue les effets d'une immunothérapie au Sipuleucel-T après un traitement anti-androgénique
Randomized Trial of Autologous Cellular Immunotherapy with Sipuleucel-T in Androgen-Dependent Prostate Cancer
Clinical Cancer Research, 2011
-
Menée in vitro et in vivo, cette étude montre qu'une légère hyperthermie (41-42,5°C) permet notamment de sensibiliser les cellules cancéreuses à un inhibiteur de PARP
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
Proceedings of the National Academy of Sciences, 2011
-
Menée in vitro, cette étude montre que la surexpression de la télomérase est associée à l'apparition d'une résistance à l'imatinib dans les cellules de leucémie myéloïde chronique
hTERT Promotes Imatinib Resistance in Chronic Myeloid Leukemia Cells: Therapeutic Implications
2011
-
Mené sur 43 patientes atteintes d'un cancer du sein résistant à une hormonothérapie, cet essai de phase II évalue le vorinostat, un inhibiteur d'histone déacétylase, en combinaison avec du tamoxifène
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
British Journal of Cancer, 2011
-
Cette étude montre que la surexpression de la protéine CUEDC2 confère aux cellules de cancer du sein une résistance à un traitement endocrinien, notamment au tamoxifène
Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer
Nature Medicine, 2011
-
Cet article passe en revue les nouvelles stratégies de traitement des métastases osseuses chez des patients atteints d'un cancer de la prostate
Bone metastasis in prostate cancer: emerging therapeutic strategies
Nature Reviews Clinical Oncology, 2011
-
File
Mené sur 168 patientes atteintes d'un cancer du sein métastatique, cet essai de phase II évalue l'ajout d'axitinib à un traitement au docétaxel
-
Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial
The Lancet Oncology, 2024
-
Solidifying local ablation in the treatment of small-size colorectal liver metastasis
The Lancet Oncology, 2024
-
Thermal ablation versus surgical resection of small-size colorectal liver metastases (COLLISION): an international, randomised, controlled, phase 3 non-inferiority trial
The Lancet Oncology, 2024
-
-
Mantle cell lymphoma: is it time for risk-adapted treatment?
The Lancet Oncology, 2024
-
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
The Lancet Oncology, 2024
-
Dual checkpoint blockade for microsatellite instability-high colorectal cancer
The Lancet, 2024
-
Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
The Lancet, 2024
-
Stereotactic Body Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer—Is This the Future?
JAMA Oncology, 2024
-
Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non–Small Cell Lung Cancer: A Nonrandomized Controlled Trial
JAMA Oncology, 2024
-
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial
JAMA Oncology, 2024
-
Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial
The Lancet Oncology, 2024
-
Harnessing stereotactic precision in the fight against primary kidney cancer: time for a randomised trial?
The Lancet Oncology, 2024
-
-
Robotic pancreatoduodenectomy: preparing for the future
The Lancet Gastroenterology & Hepatology, 2024
-
Effect of robotic versus open pancreaticoduodenectomy on postoperative length of hospital stay and complications for pancreatic head or periampullary tumours: a multicentre, open-label randomised controlled trial
The Lancet Gastroenterology & Hepatology, 2024
-
-
Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial
2023
-
Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial
2023
-
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases
New England Journal of Medicine, 2023
-
Axillary Dissection — The Bell Tolls for Thee
New England Journal of Medicine, 2023
-
Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
2023
-
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial
2023
-
Androgen deprivation therapy combined with postoperative radiotherapy for prostate cancer management
2023
-
-
-
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
2023
-
Measurable residual disease-driven therapy after radiotherapy for early-stage follicular lymphoma
2023
-
Local radiotherapy and measurable residual disease-driven immunotherapy in patients with early-stage follicular lymphoma (FIL MIRO): final results of a prospective, multicentre, phase 2 trial
2023
-
-
Quality of Life and Nutritional Outcomes of Stomach-Preserving Surgery for Early Gastric Cancer: A Secondary Analysis of the SENORITA Randomized Clinical Trial
2023
-
Laparoscopic Sentinel Node Navigation Surgery for Quality of Life Gains: When Is Less More?
2023
-
-
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial
2023
-
Immunotherapeutics in nasopharyngeal carcinoma: a relentless CONTINUUM of success
2023
-
Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial
2023
-
Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial
2023
-
Bladder Adjuvant RadioTherapy (BART): Acute and Late Toxicity from a Phase III Multicentre Randomized Controlled Trial: Acute and late toxicity in BART RCT
2023
-
Can We Offset Local Recurrence in Locally Advanced Non–Small Cell Lung Cancer? The Merry-Go-Round of Radiation Dose Escalation and Stubborn Outcomes
Journal of Clinical Oncology, 2023
-
Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial
2023
-
Primary Results of NRG-RTOG1106/ECOG-ACRIN 6697: A Randomized Phase II Trial of Individualized Adaptive (chemo)Radiotherapy Using Midtreatment 18 F-Fluorodeoxyglucose Positon Emission Tomography/Computed Tomography in Stage III Non-Small Cell Lung Cancer
Journal of Clinical Oncology, 2023
-
-
One step closer to the end of postoperative radioactive iodine thyroid remnant ablation
2023
-
Laparoscopy-assisted versus open surgery for low rectal cancer (LASRE): 3-year survival outcomes of a multicentre, randomised, controlled, non-inferiority trial
2023
-
-
Adjuvant radiation therapy for locally advanced bladder cancer: A safe and promising emerging treatment option
2023
-
-
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial
JAMA, 2023
-
-
Thyroidectomy without radioiodine in patients with low-risk thyroid cancer: 5 years of follow-up of the prospective randomised ESTIMABL2 trial
2023
-
-